What is Zacks Research's Estimate for Chemours Q2 Earnings?

The Chemours Company (NYSE:CC - Free Report) - Analysts at Zacks Research decreased their Q2 2025 EPS estimates for shares of Chemours in a research note issued to investors on Wednesday, July 9th. Zacks Research analyst R. Department now anticipates that the specialty chemicals company will post earnings per share of $0.40 for the quarter, down from their prior forecast of $0.47. The consensus estimate for Chemours' current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours' Q3 2025 earnings at $0.48 EPS, FY2025 earnings at $1.32 EPS, Q1 2026 earnings at $0.35 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.70 EPS, Q4 2026 earnings at $0.41 EPS, FY2026 earnings at $2.10 EPS, Q1 2027 earnings at $0.49 EPS and FY2027 earnings at $2.44 EPS.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). The business had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.36 billion. Chemours had a net margin of 0.54% and a return on equity of 23.82%. The company's revenue was up .4% on a year-over-year basis. During the same period last year, the business earned $0.32 earnings per share.

Several other research analysts have also recently weighed in on the stock. Royal Bank Of Canada boosted their price objective on shares of Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a report on Thursday, July 3rd. The Goldman Sachs Group decreased their price objective on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. Truist Financial decreased their price objective on shares of Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a report on Monday, April 14th. Morgan Stanley decreased their price objective on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a report on Monday, May 12th. Finally, Barclays reduced their target price on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, May 28th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $17.33.

Chemours Stock Performance

Shares of CC traded down $0.24 during mid-day trading on Thursday, hitting $13.81. 3,892,089 shares of the company traded hands, compared to its average volume of 2,537,633. The company has a debt-to-equity ratio of 7.01, a quick ratio of 0.83 and a current ratio of 1.75. The stock has a 50-day moving average price of $11.38 and a two-hundred day moving average price of $13.96. Chemours has a 1 year low of $9.13 and a 1 year high of $25.54. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of 69.05 and a beta of 1.65.

Chemours Dividend Announcement

The company also recently declared a dividend, which was paid on Monday, June 16th. Shareholders of record on Monday, May 19th were given a $0.0875 dividend. The ex-dividend date was Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's payout ratio is currently 175.00%.

Insider Buying and Selling

In other news, insider Damian Gumpel purchased 13,400 shares of the company's stock in a transaction on Monday, June 2nd. The stock was acquired at an average cost of $9.22 per share, for a total transaction of $123,548.00. Following the completion of the transaction, the insider directly owned 123,879 shares in the company, valued at $1,142,164.38. This trade represents a 12.13% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Shane Hostetter purchased 4,450 shares of the company's stock in a transaction on Monday, May 19th. The stock was purchased at an average price of $11.28 per share, with a total value of $50,196.00. Following the completion of the transaction, the chief financial officer owned 59,694 shares of the company's stock, valued at approximately $673,348.32. This trade represents a 8.06% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 25,672 shares of company stock valued at $251,573. Company insiders own 0.47% of the company's stock.

Hedge Funds Weigh In On Chemours

Hedge funds and other institutional investors have recently modified their holdings of the stock. FNY Investment Advisers LLC bought a new position in Chemours during the first quarter valued at $27,000. UMB Bank n.a. lifted its position in Chemours by 73.9% during the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after purchasing an additional 948 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Chemours by 170.7% during the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after purchasing an additional 1,444 shares during the last quarter. SouthState Corp bought a new position in Chemours during the first quarter valued at $34,000. Finally, Quadrant Capital Group LLC lifted its position in Chemours by 100.4% during the fourth quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock valued at $38,000 after purchasing an additional 1,119 shares during the last quarter. Institutional investors own 76.26% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.